Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Prudential Financial Inc.

Prudential Financial Inc. grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 8.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 41,193 shares of the company's stock after buying an additional 3,254 shares during the period. Prudential Financial Inc. owned 0.14% of Krystal Biotech worth $6,815,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares during the period. State Street Corp grew its holdings in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock worth $264,455,000 after purchasing an additional 119,936 shares during the period. Geode Capital Management LLC increased its position in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock worth $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Franklin Resources Inc. raised its holdings in Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after buying an additional 62,178 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Krystal Biotech by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock valued at $38,095,000 after buying an additional 2,954 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Krystal Biotech Trading Down 3.8 %

KRYS stock traded down $6.83 during midday trading on Friday, hitting $171.30. 444,673 shares of the company's stock were exchanged, compared to its average volume of 291,834. The firm has a 50 day moving average price of $173.27 and a 200-day moving average price of $173.18. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The stock has a market capitalization of $4.93 billion, a price-to-earnings ratio of 57.29 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the firm earned $0.30 earnings per share. The business's revenue was up 116.4% compared to the same quarter last year. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on KRYS. Citigroup increased their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Chardan Capital raised their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).